NDA 018948 · Leadiant Biosci INC
Carnitor
Levocarnitine · Oral · Carnitine Analog
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 17, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 27, 1985
Approved uses
2
Original approval plus efficacy supplements
Registered trials
188
46 Phase 3, 12 recruiting
FAERS reports
3,646
2,818 serious, 395 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2024.
INDICATIONS AND USAGE CARNITOR ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. CARNITOR ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 16, 1992 Supplement 9 · Efficacy
- Dec 27, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
2 products under this application
- CARNITOR · LEVOCARNITINE 1GM/10ML · SOLUTION, ORAL · Discontinued
- CARNITOR · LEVOCARNITINE 330MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Levocarnitine" as an intervention, any sponsor and status, largest first.
The First Affiliated Hospital of Zhejiang Chinese Medical UniversityAcademic, hospital or other
NCT05673239 · 1,008 participants · Start Jan 15, 2023 · Primary completion Jun 30, 2023
Drug: Levocarnitine Injection · For: Renal Dialysis
Sites: Hangzhou, China
- Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular DiseasePivotal-lookingStatus unknown
Hanmi Pharmaceutical Company LimitedIndustry
NCT04346862 · 636 participants (planned) · Start Jan 26, 2016 · Primary completion Jun 30, 2020
Drug: Acetyl-L-carnitine hydrochloride 500mg; Placebo · For: Mild Cognitive Impairment
Sites: Incheon, South Korea
- The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001082 · 505 participants · Start Dec 1996 · Primary completion Jan 1999
Drug: Levocarnitine; Adefovir dipivoxil and 1 more · For: Cytomegalovirus Infections; HIV Infections
Sites: San Francisco, California; Denver, Colorado; Washington D.C., District of Columbia · 15 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000912 · 475 participants
Drug: Indinavir sulfate; Abacavir sulfate and 6 more · For: HIV Infections
Sites: Los Angeles, California; Menlo Park, California; San Diego, California · 45 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000885 · 440 participants
Drug: Indinavir sulfate; Abacavir sulfate and 8 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 53 sites in all
- Atorvastatin, L-Carnitine and Non-Alcoholic SteatohepatitisPivotal-lookingStatus unknown
Tehran University of Medical SciencesAcademic, hospital or other
NCT01617772 · 440 participants (planned) · Start Jan 1, 2016 · Primary completion Oct 2019
Drug: Atorvastatin; L-Carnitine and 1 more · For: Non-alcoholic Steatohepatitis
Sites: Shiraz, Iran; Tehran, Iran
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaPivotal-lookingActive, not recruiting
Children's Oncology GroupResearch network
NCT05602194 · 440 participants (planned) · Start Aug 24, 2023 · Primary completion Sep 30, 2026
Drug: Calaspargase Pegol; Pegaspargase · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 228 sites in all
- Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled TrialPivotal-lookingNot yet recruiting
Hamad Medical CorporationIndustry
NCT07862725 · 360 participants (planned) · Start Oct 15, 2026 · Primary completion Oct 15, 2027
Drug: Antioxidants + Clomiphene Citrate; Antioxidants + FSH and 1 more · For: Oligoasthenoteratozoospermia; Male Infertility
Sites: Doha, Qatar
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure391
- off label use309
- vomiting230
- diarrhoea210
- drug ineffective195
- fatigue185
- pneumonia182
- pyrexia174
- nausea135
- product dose omission issue133
- somnolence131
- decreased appetite123
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 23 |
| 2005 | 17 |
| 2006 | 12 |
| 2007 | 28 |
| 2008 | 53 |
| 2009 | 32 |
| 2010 | 30 |
| 2011 | 34 |
| 2012 | 57 |
| 2013 | 71 |
| 2014 | 80 |
| 2015 | 124 |
| 2016 | 226 |
| 2017 | 159 |
| 2018 | 195 |
| 2019 | 228 |
| 2020 | 271 |
| 2021 | 255 |
| 2022 | 356 |
| 2023 | 411 |
| 2024 | 408 |
| 2025 | 353 |
| 2026 | 223 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Carnitor (Levocarnitine (With Sugar))
2024 spending
$46K
Beneficiaries
18
113 claims
Per beneficiary
$2,552
$0.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $67,696 |
| 2021 | $55,647 |
| 2022 | $55,240 |
| 2023 | $55,962 |
| 2024 | $45,944 |
Part D: Carnitor* (Levocarnitine)
2024 spending
$226K
Beneficiaries
205
981 claims
Per beneficiary
$1,101
$1.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $451,470 |
| 2021 | $387,772 |
| 2022 | $543,715 |
| 2023 | $442,821 |
| 2024 | $225,745 |
Part B: Carnitor* (Levocarnitine*) · HCPCS J1955
2024 spending
$3.4M
Beneficiaries
1,549
23,222 claims
Per beneficiary
$2,214
2024 ASP limit $32.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,611,342 |
| 2021 | $16,231,026 |
| 2022 | $11,067,747 |
| 2023 | $5,607,416 |
| 2024 | $3,428,722 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Wang Y, Hao Q, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- The effect of levocarnitine supplementation on dialysis-related hypotension: A systematic review, meta-analysis, and trial sequential analysis.
Chewcharat A, Chewcharat P, Liu W, et al. · PLoS One 2022 · Meta-Analysis, Systematic Review
- [on oligozoospermia and asthenospermia].
Li ML, Wu GJ, Zhou ZH, et al. · Zhonghua Nan Ke Xue 2020 · Randomized Controlled Trial
- Levocarnitine normalizes elevated blood level of soluble Fas mRNA in patients with acute myocardial infarction.
Novikov DV, Belousov SS, Karaulov AV, et al. · Bull Exp Biol Med 2015 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- METHOD FOR PREVENTION OF COAGULOPATHIC BLEEDING DURING SURGERY FOR MECHANICAL JAUNDICE.
Orazgalieva M, Aimagambetov M, Abdrakhmanov S, et al. · Georgian Med News 2024 · Randomized Controlled Trial
- Effects of L-carnitine in patients with hepatic encephalopathy.
Malaguarnera M, Pistone G, Elvira R, et al. · World J Gastroenterol 2005 · Randomized Controlled Trial
Sponsor: Leadiant Biosci INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.